Revance Therapeutics, Inc.

NasdaqGM:RVNC Stock Report

Market Cap: US$323.1m

Revance Therapeutics Valuation

Is RVNC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RVNC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RVNC ($3.08) is trading below our estimate of fair value ($78.22)

Significantly Below Fair Value: RVNC is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RVNC?

Key metric: As RVNC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for RVNC. This is calculated by dividing RVNC's market cap by their current revenue.
What is RVNC's PS Ratio?
PS Ratio1.3x
SalesUS$256.95m
Market CapUS$323.10m

Price to Sales Ratio vs Peers

How does RVNC's PS Ratio compare to its peers?

The above table shows the PS ratio for RVNC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.3x
ACRS Aclaris Therapeutics
11.5x5.5%US$310.3m
ETON Eton Pharmaceuticals
9.4x34.8%US$327.1m
XERS Xeris Biopharma Holdings
2.8x17.2%US$517.3m
ESPR Esperion Therapeutics
1.5x28.3%US$453.2m
RVNC Revance Therapeutics
1.3x20.6%US$323.1m

Price-To-Sales vs Peers: RVNC is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (6.3x).

Price to Sales Ratio vs Industry

How does RVNC's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

68 CompaniesPrice / SalesEstimated GrowthMarket Cap
OGN Organon
0.6x0.02%US$3.79b
PRGO Perrigo
0.8x3.4%US$3.50b
BHC Bausch Health Companies
0.3x1.5%US$2.77b
PAHC Phibro Animal Health
0.8x12.5%US$876.50m
RVNC 1.3xIndustry Avg. 3.0xNo. of Companies68PS03.67.210.814.418+
68 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: RVNC is good value based on its Price-To-Sales Ratio (1.3x) compared to the US Pharmaceuticals industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is RVNC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RVNC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.3x
Fair PS Ratio4.6x

Price-To-Sales vs Fair Ratio: RVNC is good value based on its Price-To-Sales Ratio (1.3x) compared to the estimated Fair Price-To-Sales Ratio (4.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RVNC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.08
US$7.64
+148.0%
95.0%US$25.00US$3.00n/a7
Dec ’25US$3.61
US$9.23
+155.6%
69.9%US$25.00US$6.00n/a7
Nov ’25US$5.80
US$9.23
+59.1%
69.9%US$25.00US$6.00n/a7
Oct ’25US$5.20
US$9.23
+77.4%
69.9%US$25.00US$6.00n/a7
Sep ’25US$6.57
US$9.65
+46.9%
66.1%US$25.00US$6.00n/a7
Aug ’25US$3.37
US$13.50
+300.6%
46.6%US$25.00US$6.00n/a12
Jul ’25US$2.57
US$13.50
+425.3%
46.6%US$25.00US$6.00n/a12
Jun ’25US$2.84
US$13.50
+375.4%
46.6%US$25.00US$6.00n/a12
May ’25US$3.80
US$16.33
+330.4%
51.5%US$32.00US$6.00n/a12
Apr ’25US$4.73
US$16.33
+245.3%
51.5%US$32.00US$6.00n/a12
Mar ’25US$6.98
US$16.33
+134.0%
51.5%US$32.00US$6.00n/a12
Feb ’25US$5.15
US$20.08
+290.0%
62.4%US$46.00US$8.00n/a12
Jan ’25US$8.79
US$26.92
+206.2%
45.4%US$46.00US$9.00n/a12
Dec ’24US$7.24
US$26.92
+271.8%
45.4%US$46.00US$9.00US$3.6112
Nov ’24US$7.93
US$35.83
+351.9%
36.6%US$65.00US$12.00US$5.8012
Oct ’24US$11.47
US$37.33
+225.5%
31.0%US$65.00US$15.00US$5.2012
Sep ’24US$18.16
US$39.83
+119.3%
27.6%US$65.00US$20.00US$6.5712
Aug ’24US$23.04
US$40.67
+76.5%
26.8%US$65.00US$21.00US$3.3712
Jul ’24US$25.31
US$40.58
+60.3%
27.0%US$65.00US$21.00US$2.5712
Jun ’24US$30.41
US$39.62
+30.3%
27.7%US$65.00US$21.00US$2.8413
May ’24US$32.29
US$37.38
+15.8%
27.5%US$65.00US$20.00US$3.8013
Apr ’24US$32.21
US$37.38
+16.1%
27.5%US$65.00US$20.00US$4.7313
Mar ’24US$32.25
US$36.54
+13.3%
30.2%US$65.00US$20.00US$6.9813
Feb ’24US$34.38
US$35.46
+3.1%
30.4%US$65.00US$20.00US$5.1513
Jan ’24US$18.46
US$33.38
+80.8%
32.6%US$65.00US$19.00US$8.7913
Dec ’23US$21.76
US$34.58
+58.9%
30.2%US$65.00US$22.00US$7.2412

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 08:26
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Revance Therapeutics, Inc. is covered by 22 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Difei YangAegis Capital Corporation
Balaji PrasadBarclays
Balaji PrasadBarclays